Tender Clause 21.1(g) | Contractual Blacklisting for NSQ Drugs Not Vitiated by Drug Inspectorate Procedural Lapses: Karnataka HC

The Karnataka High Court has clarified that a public procurement entity may enforce contractual blacklisting for supply of "Not of Standard Quality" drugs under tender conditions, even where statutory procedures under the Drugs and Cosmetics Act, 1940 were not followed by the testing authority. The judgment underscores the distinction between statutory compliance and contractual enforcement in public health procurement.

Background & Facts

The Dispute

The petitioner, Biogenic Drugs Private Limited, a pharmaceutical manufacturer based in Jaipur, participated in a tender issued by the Karnataka State Medical Supplies Corporation Limited (KSMSCL), the respondent, for the supply of 4,46,724 units of Ferrous Salts (A) + Folic Acid (B) 45 mg elemental Iron (A) + 400 mcg (B) Pink Tablets. The petitioner was declared the successful bidder on the basis of its bid and entered into a purchase order valued at Rs. 46,45,929/-.

Key Facts

• The petitioner supplied the drugs in accordance with the purchase order.
• The drugs were accompanied by NABL-accredited laboratory test reports and the petitioner’s in-house quality control reports.
• Upon receipt, the respondent subjected the consignment to quality testing through its Drug Inspectorate.
• The Government Analyst, acting under the Drugs and Cosmetics Act, 1940, issued a report declaring the batch as "Not of Standard Quality" (NSQ).
• The respondent issued three replacement notices: 24.01.2025, 27.02.2025, and 28.02.2025, directing the petitioner to replace the NSQ drugs.
• The petitioner did not replace the drugs.
• The petitioner contended that it was never furnished with a copy of the Government Analyst’s report or the statutory sample portions, thereby denying it the right to seek re-analysis under the Drugs and Cosmetics Act, 1940.
• On 06.03.2025, the respondent issued a show-cause notice invoking Clause 21.1(g) of the tender conditions, proposing a three-year blacklisting.
• The petitioner replied on 07.03.2025, reiterating its procedural objections and requesting deferment of action.
• On 28.03.2025, the respondent passed the impugned order blacklisting the petitioner for three years under Clause 21.1(g).

Procedural History

• 05.05.2023: Tender notification issued by KSMSCL for procurement of iron tablets.
• Late 2023: Petitioner awarded contract; supply completed.
• January 2025: Government Analyst’s report issued declaring batch NSQ.
• 24.01.2025: First replacement notice issued.
• 27.02.2025: Second replacement notice issued.
• 28.02.2025: Third replacement notice issued.
• 06.03.2025: Show-cause notice issued proposing three-year blacklisting under Clause 21.1(g).
• 07.03.2025: Petitioner’s reply submitted.
• 28.03.2025: Impugned blacklisting order passed.
• 25.04.2025: Writ Petition (WP No. 25026 of 2025) filed before the Karnataka High Court.
• 01.06.2026: Writ petition heard and reserved.
• 09.06.2026: Judgment pronounced.

The Parties' Positions

Petitioner (Biogenic Drugs Private Limited): Argued that the blacklisting was invalid because:

• The Government Analyst’s report was not furnished, violating the Drugs and Cosmetics Act, 1940.
• The statutory right to seek re-analysis was denied.
• The action was tantamount to debarment under Rule 26A of the Karnataka Transparency in Public Procurements Rules, 2000, which mandates a Debarment Committee and oral hearing.
• The penalty of three years was disproportionate for a single batch failure.

Respondent (KSMSCL): Contended that:

• The action was taken under Clause 21.1(g) of the tender conditions, not Rule 26A.
• Clause 21.1(g) permits blacklisting for failure of quality in two or more batches, irrespective of intent.
• The petitioner was given multiple notices and a full opportunity to respond.
• The Government Analyst’s report, until set aside, is presumed valid and may be acted upon.
• The petitioner’s failure to replace the drugs independently justified the action.

Relief Sought

The petitioner sought:

• Quashing of the blacklisting order dated 28.03.2025.
• Restoration of its eligibility to participate in future tenders.
• A direction to the respondent to refrain from enforcing the blacklisting.
• Costs.

The Legal Issue

The central question was whether a public procurement entity may impose a three-year blacklisting under a contractual clause (Clause 21.1(g)) for supply of "Not of Standard Quality" drugs, even if the underlying Government Analyst’s report was not furnished to the supplier in compliance with the Drugs and Cosmetics Act, 1940, and whether such action requires compliance with the statutory procedure under Rule 26A of the Karnataka Transparency in Public Procurements Rules, 2000.

Arguments Presented

For the Appellant/Petitioner

The petitioner relied on Erusian Equipment and Chemicals Limited v. State of West Bengal, Kulja Industries Limited v. Bharat Sanchar Nigam Limited, and Daffodils Pharmaceutics Limited v. State of Uttar Pradesh to argue that blacklisting constitutes a severe civil consequence, akin to "civil death," and triggers the principles of natural justice. It contended that Rule 26A of the Karnataka Transparency in Public Procurements Rules, 2000, being the only statutory framework governing debarment, must apply to all such actions by a Procurement Entity, regardless of whether the ground is fraud or quality failure. It further argued that the non-furnishing of the Government Analyst’s report and statutory sample portions rendered the foundation of the action legally defective, and that the petitioner was denied an effective opportunity to defend itself. The petitioner submitted that the absence of an oral hearing and a Debarment Committee rendered the order procedurally invalid.

For the Respondent/State

The respondent argued that Clause 21.1(g) of the tender conditions was a freely accepted contractual provision, distinct from Rule 26A, which governs corrupt or fraudulent practices. It emphasized that the petitioner had voluntarily agreed to the consequences of supplying NSQ drugs, including a minimum three-year blacklisting. The respondent contended that it was not obligated to furnish the Government Analyst’s report, as it was not the testing authority; the report was a statutory document presumed valid until overturned. It further argued that the petitioner had been afforded a reasonable opportunity through replacement notices, a specific show-cause notice, and a detailed written reply, and that an oral hearing was not mandatory in contractual contexts. The respondent relied on Isolators and Isolators v. MP Vidyut Vitran Company and Sujal Pharma v. KSMSCL to affirm that fairness, not rigid procedure, is the standard.

The Court's Analysis

The Court undertook a structured analysis of the source of power, procedural obligations, and the nature of the sanction. It first determined that the impugned order was not issued under Rule 26A of the Karnataka Transparency in Public Procurements Rules, 2000, but under Clause 21.1(g) of the tender conditions. Rule 26A requires proof of corrupt or fraudulent conduct, whereas Clause 21.1(g) is triggered by objective quality failure in laboratory testing - a distinct and non-moral ground. The Court held that a contractual provision cannot be subsumed under a statutory provision merely because the consequence is severe; the source of authority must be respected.

"The substratum of Rule 26A is, therefore, misconduct in the nature of corruption, fraud, or misrepresentation. Clause 21.1(g) is concerned with quality failure, a factual/technical matter unconnected with fraud or corruption. The two provisions are not in conflict but are complementary."

The Court then examined whether the non-furnishing of the Government Analyst’s report and sample portions under the Drugs and Cosmetics Act, 1940 vitiated the respondent’s action. It held that the Drug Inspectorate, not the respondent, was bound by the statutory procedure. The respondent, as a procurement entity, was entitled to rely on the report as a presumptively valid public document. The petitioner’s remedy, if any, lay against the Drug Inspectorate - not against the respondent’s contractual enforcement.

"The respondent received the Government Analyst’s report from the competent authority. The report carries a statutory presumption of correctness. Unless and until it is set aside by a competent forum, the respondent is entitled to act upon it in exercise of its contractual rights."

On the question of natural justice, the Court acknowledged the gravity of blacklisting but held that the petitioner had been afforded a reasonable opportunity. The show-cause notice was specific, the petitioner submitted a detailed reply addressing all grounds, and the respondent considered the submissions. The absence of an oral hearing was not fatal, given the clarity of the factual basis (NSQ report + non-replacement) and the absence of any counter-evidence from the petitioner.

"Fairness does not always require formal oral hearings; it requires that the affected party knows the case against it, knows the proposed action, and has a genuine opportunity to respond."

The Court further rejected the argument of disproportionality. The three-year blacklisting was the minimum penalty under Clause 21.1(g), which the petitioner had accepted. Given the public health imperative - ensuring that sub-standard drugs do not enter the public healthcare system - the penalty was rationally connected to the objective.

"The respondent’s primary obligation is to protect public health. Sub-standard drugs in the public healthcare system can cause serious harm to patients... A three-year blacklisting, which is the minimum contractual consequence, cannot be said to be excessive in this context."

The Court concluded that the action was neither arbitrary nor procedurally flawed, and that the petitioner’s failure to challenge the report in the appropriate forum undermined its claim of prejudice.

The Verdict

The writ petition was dismissed. The Karnataka High Court upheld the blacklisting order dated 28.03.2025, finding it validly issued under Clause 21.1(g) of the tender conditions. The Court held that the respondent was justified in acting on the Government Analyst’s report, that the petitioner was afforded a reasonable opportunity of hearing, and that compliance with Rule 26A was not mandatory. The petitioner’s remedy, if any, lies in challenging the Government Analyst’s report under the Drugs and Cosmetics Act, 1940, before the competent authority. No monetary relief, costs, or directions for reinstatement were granted.

What This Means For Similar Cases

Contractual Blacklisting Is Not Subject to Statutory Debarment Procedures

• Practitioners must distinguish between statutory debarment (Rule 26A) and contractual blacklisting (tender clauses). The former requires a Debarment Committee and oral hearing; the latter does not.
• Procurement entities may enforce pre-agreed contractual penalties for quality failures without complying with Rule 26A, provided the clause is clear and unambiguous.
• The source of power - statutory or contractual - determines the applicable procedure.

Statutory Defects in Testing Do Not Invalidate Contractual Enforcement

• A supplier cannot use procedural lapses by a third-party statutory authority (e.g., Drug Inspectorate) as a shield against contractual consequences.
• Unless the report is set aside by a competent forum, the procurement entity may rely on it as a valid basis for action.
• Suppliers must pursue statutory remedies separately; they cannot delay or block contractual enforcement by merely alleging procedural defects.

Natural Justice in Contractual Blacklisting Requires Substance, Not Form

• An oral hearing is not mandatory in every case; a specific show-cause notice and meaningful written reply may suffice.
• The key is whether the affected party had a real opportunity to respond to the allegations and evidence.
• Where the factual basis is objective (e.g., NSQ report) and the supplier fails to provide counter-evidence, the absence of an oral hearing does not vitiate the order.
• Practitioners should advise clients to submit detailed, evidence-based replies to show-cause notices - even if procedural objections are raised - to satisfy the test of fairness.